Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

9.660 USD +0.290 (+3.09%)
Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Inovio Pharma

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to... 
From GlobeNewswire News Releases
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
First efficacy trial to evaluate Inovio’s cancer immunotherapy targeting HPV in combination with durvalumab 
From GlobeNewswire News Releases
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales 
From GlobeNewswire News Releases
Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen
From PR Newswire
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
New strategic position will guide product discovery and scientific collaborations 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
Former Chief Marketing Officer at Merck Also Brings Women’s Health Management Expertise 
From GlobeNewswire News Releases
Detailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins, Sprouts Farmers Market, and Inovio Pharmaceuticals — What Drives Growth in Today's Competitive Lan
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CVS Health Corporation... 
From GlobeNewswire News Releases
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product 
From GlobeNewswire News Releases
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint... 
From GlobeNewswire News Releases
Biotechnology and Oncology Markets Have Positive Projections
FinancialBuzz.com News Commentary 
From PR Newswire
Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
Inovio’s cancer immunotherapies show antigen-specific T-cell stimulation in head and neck and other solid tumors 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
Phase 1b/2a clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s T cell activator INO-5401 in brain cancer 
From GlobeNewswire News Releases
Biotech Companies With Advantageous Tech for Cancer Patients
MicroCapSpeculators.com News Commentary 
From PR Newswire
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 third quarter financial results on Wednesday, November 8, 2017 at 4:30... 
From GlobeNewswire News Releases
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever... 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
Trial to evaluate Inovio’s INO-5401 and Genentech’s TECENTRIQ® in patients with metastatic bladder cancer 
From GlobeNewswire News Releases
Tracking Pre-Clinical Data in Biotech: Risk Versus Reward
MicroCapSpeculators.com News Commentary 
From PR Newswire
Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
Phase 1 results show GLS-5700 induced high levels of antibodies in 100% of participants; Serum from vaccinated subjects prevented infection in virus challenge in animals 
From GlobeNewswire News Releases
Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
Inovio’s DNA-based Monoclonal Antibody Programs Boosted by Scientific Publications 
From GlobeNewswire News Releases
Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
Korean trial is fully funded by partners and will evaluate Inovio’s advanced intradermal delivery system 
From GlobeNewswire News Releases
Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study 
From GlobeNewswire News Releases
Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies
From PR Newswire
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2017. 
From GlobeNewswire News Releases
How These Biotech Stocks are Performing? -- Inovio Pharma, Intra Cellular Therapies, OncoMed Pharma, and Ophthotech
From PR Newswire
Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second quarter financial results on Tuesday, August 8, 2017 at 4:30... 
From GlobeNewswire News Releases
Inovio Announces Pricing of Public Offering of Common Stock
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share.... 
From GlobeNewswire News Releases
Inovio Announces Proposed Public Offering of Common Stock
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering. Inovio expects to grant the... 
From GlobeNewswire News Releases
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.